Document is current
Any future updates will be listed below
-
Authors
Sakaguchi, Ryoko https://orcid.org/0009-0000-8844-9811
Joh, Kensuke https://orcid.org/0000-0002-9334-3664
Honma, Shiko https://orcid.org/0009-0005-7402-5125
Shimizu, Akira
Hashiguchi, Akinori https://orcid.org/0000-0002-6455-071X
Katafuchi, Ritsuko https://orcid.org/0009-0002-0360-1568
Nishikawa, Masako https://orcid.org/0000-0001-6649-9535
Koike, Kentaro
Hirano, Keita https://orcid.org/0000-0003-2313-8937
Tsuboi, Nobuo https://orcid.org/0000-0002-5407-5265
Kawamura, Tetsuya https://orcid.org/0000-0002-8376-5273
Yokoo, Takashi https://orcid.org/0000-0003-1838-7998
Suzuki, Yusuke https://orcid.org/0000-0002-4077-9747
- License Information
-
More Information
Article History
Received: 9 September 2025
Accepted: 21 January 2026
First Online: 2 February 2026
Declarations
:
: Y.S. has received consulting fees from Otsuka Pharmaceutical, Novartis, Chinook Therapeutics, Argenx, BioCryst, Alexion Pharmaceuticals, Renalys, Alpine, and George Clinical. Y.S. has also received compensation for academic or educational activities from Kyowa Kirin, Novartis, Mitsubishi Tanabe, Otsuka Pharmaceutical, DAIICHI SANKYO, AstraZeneca, Boehringer Ingelheim, and Chinook Therapeutics. The remaining authors have no competing interests to declare.
